Allarity Therapeutics, Inc. (ALLR): Nasdaq/NYSE listing notice — Dec 20, 2022: Allarity Therapeutics (ALLR) gets Nasdaq deficiency notice for MVPHS non-compliance

Allarity Therapeutics, Inc.

Nasdaq notice: MVPHS below $5M for 31 consecutive business days through Dec 19, 2022.
Compliance period of 180 days until June 19, 2023; must close at $5M for 10 consecutive business days.
If not compliant by deadline, company may face delisting from Nasdaq Global Market.
Company intends to monitor MVPHS and evaluate available options to regain compliance.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Allarity Therapeutics, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(1)(C), 5810(c)(3)(D)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5450(b)(1)(C), 5810(c)(3)(D)

Exact text from the filing

December 20, 2022, the Company received a written notice (the “Notice”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the minimum Market Value of Publicly Held Shares (“MVPHS”) of $5,000,000 under the Nasdaq Listing Rules (the “Listing Rules”). Based on the Company’s MVPHS for the last thirty-one (31) consecutive business days from November 4, 2022 to December 19, 2022, the Company no longer meets the minimum MVPHS requirement set forth in Listing Rule 5450(b)(1)(C). The Notice is only a notificatio

View on SEC.gov

19 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Allarity Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-22-081611

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.